Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
904 articles by Ben Fidler
-
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
July 15, 2026 -
Agenus surges on study pivot; Apnimed lines up an IPO
July 13, 2026 -
AstraZeneca, Ionis drug fails big heart disease study in major setback
July 9, 2026 -
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
July 8, 2026 -
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
July 7, 2026 -
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
June 24, 2026 -
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
June 22, 2026 -
Pfizer CFO to step down; Denali sells a regulatory fast-pass
June 18, 2026 -
Roche stakes $700M on Nurix’s protein-degrading drug
June 8, 2026 -
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
June 8, 2026 -
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
June 2, 2026 -
Allogene CEO to step down; Agios drug fails key test
May 29, 2026 -
Pfizer, Innovent strike $10B cancer drug deal
May 29, 2026 -
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
May 26, 2026 -
Relay drug shows early promise against rare blood vessel diseases
May 19, 2026 -
Regeneron immunotherapy combo comes up short in melanoma trial
May 18, 2026 -
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
May 14, 2026 -
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
May 12, 2026 -
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
May 12, 2026 -
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
May 11, 2026 -
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
May 8, 2026 -
Avalo shares spike on skin drug data; BioNTech to cut staff
May 6, 2026 -
Cytokinetics heart drug scores in closely watched trial
May 5, 2026 -
With $97M, Latus pursues a different kind of Huntington’s gene therapy
May 4, 2026 -
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
May 4, 2026
